The global kidney cancer drugs market was valued at about $3.3 billion in 2018. North America was the largest region in the kidney cancer drugs market in 2018. The kidney cancer drugs market (https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report) consists of sales of kidney cancer drugs. It includes immunotherapy, chemotherapy and targeted therapy.
Rise in incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Change in lifestyles of people, consumption of tobacco, and unhealthy diet are some factors which contribute to the growth of these renal cancer cells. According to the American Cancer Society Report 2018, an estimated 65,340 new cases of kidney (renal) cancer were diagnosed in the US in 2018. In 2014, the estimation was around 63,920 new cases. Thus, this is driving the growth of the kidney cancer drugs market. Increasing use of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market.
Use of combination therapy is trending in the kidney (renal) cancer drugs market. Combination therapy combines the effects of various drugs thereby reducing the likelihood of cancer resistant cells from developing. The improved understanding about renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood are combined with inhibitors of mammalian target of rapamycin (mTor), which helps promote cellular biogenesis. According to a study conducted by National cancer institute (NIH) in 2019, the combination treatment leads to better outcomes in the patients suffering from advanced kidney cancer.
Major players in the market are Bayer AG, Pfizer Inc, Novartis International AG, Exelixis, Inc, and F. Hoffmann-La Roche AG. Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California.
Request A Sample Of The Global Kidney Cancer Drugs Market Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp
Few Points From Table of Contents:
1. Executive Summary
2. Kidney Cancer Drugs Market Characteristics
3. Kidney Cancer Drugs Market Size And Growth
4. Kidney Cancer Drugs Market Segmentation
4.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)
4.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Nexavar (Sorafenib)
Sutent (Sunitinib)
Afinitor (Everolimus)
Votrient (Pazopanib)
Avastin (Bevacizumab)
Inlyta (Axitinib),
Torisel (Temsirolimus)
Proleukin (Aldesleukin)
4.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2014-2018, 2022F, 2025F, 2030F, $ Billion
Hospitals
Clinics
Research Center
5. Kidney Cancer Drugs Market Regional And Country Analysis
Place a Direct PURCHASE Order of Complete Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2591
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Media Contact
Company Name: The Business Research Company
Contact Person: Nitin
Email: Send Email
Phone: 08897263534
Address:1st Floor, Anshu Colors Building, Road Number 1 Park View Enclave, Jubilee Hills
City: Hyderabad 500033
State: Telengana
Country: India
Website: https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report